Literature DB >> 725583

Indications for the use of tranylcypromine and trifluoperazine (Parstelin).

H A Lyons, M Degerli.   

Abstract

Thirty-two patients were treated with the combination of tranylcypromine and trifluoperazine (Parstelin). The patients fell into 3 clinical groups, namely, endogenous depression (7 patients), neurotic depressive reaction (10 patients) and phobic anxiety with some depressive features (15 patients). Satisfactory response was found in 10 out of the 15 patients with phobic symptoms. The response in the other 2 groups was not significant. Side effects were troublesome in the neurotic depressive reaction group. In the phobic group the symptoms of the patients who responded were inclined to recur when the treatment was discontinued. It is considered that it is a useful preparation in the treatment of some phobic patients, but one must expect that the patients are likely to have to remain on the drug for long periods of time.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 725583     DOI: 10.1177/003693307802300410

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  1 in total

1.  Detection and quantitation of a ring-hydroxylated metabolite of the antidepressant drug tranylcypromine.

Authors:  G B Baker; D R Hampson; R T Coutts; R G Micetich; T W Hall; T S Rao
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.